Annual report pursuant to Section 13 and 15(d)

Subsequent Events

v3.20.1
Subsequent Events
12 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
 
In addition to the subsequent events discussed elsewhere in these notes, see below for a discussion of our subsequent events occurring after December 31, 2019.

Offering

In February 2020, the Company entered into subscription agreements with certain institutional investors for the sale by the Company of up to 7,500,000 shares of common stock and warrants to purchase 5,625,000 shares of common stock at $0.80 per share and related warrant. The warrants will be exercisable six months from the date of issuance at a price of $1.05 per
share and will expire five years from the date they are first exercisable. The shares of common stock are being offered together with the warrants, but the securities will be issued separately and will be separately transferable. Total proceeds of the offering were approximately $6.0 million, prior to deducting the placement agent fees and other estimated offering expenses.

Pandemic

In March 2020, the World Health Organization declared the outbreak of a novel Coronavirus (COVID-19) as a pandemic, which continues to spread throughout the United States. The spread of COVID-19 has caused significant volatility in U.S. and international markets, including Poland, where the Company conducts some of its clinical trials and Italy, where its drug supply is produced. There has been no interruption of its drug supply, and some Polish clinics where the Company is conducting trials have limited access on monitoring activities, which for now has not slowed the progress of its trials. This could change at any time. Furthermore, there is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the US and international economies and, as such, the Company is unable to determine if it will have a material impact to its operations.